Publication: Nature 561, S48-S49 (2018); doi: 10.1038/d41586-018-06708-3
Author: Anna Nowogrodzki
Even in comparison to other types of cancer, brain cancer is particularly deadly. People with glioblastoma multiforme, one of the most common forms of brain cancer, have a median survival of less than 15 months after diagnosis. The US Food and Drug Administration (FDA) has so far approved only five drugs for treating brain cancer. Given this limited range, researchers could search for potential treatments among the wider pool of all FDA-approved drugs; however, any found to be effective would probably work in just a slim percentage of people with brain cancer.
Science Translational Medicine 09 Oct 2019: Vol. 11, Issue 513, eaay2574 DOI: 10.1126/scitranslmed.aay2574
Curr Opin Genet Dev. 2019 Mar 4;54:7-11. doi: 10.1016/j.gde.2019.02.003
Commun Biol. 2019 Feb 25;2:78. doi: 10.1038/s42003-019-0305-x. eCollection 2019.
Ann Surg Oncol. 2019 Jan;26(1):139-147. doi: 10.1245/s10434-018-7008-2. Epub 2018 Nov 9.
Human Molecular Genetics, Volume 27, Issue R2, 01 August 2018, Pages R99–R107
Nature Reviews Cancer, volume 18, pages407–418 (2018)
Subscribe to our newsletter
Stay up-to-date on the latest advancements in 3D cell culture technology